Respiratory failure & ventilation

Dyspnea is severe and associated with a higher intubation rate in de novo acute hypoxemic respiratory failure

Crit CarePublished Secondary analysis of a multicentre randomised controlled trial

An erratum to this article was published (Crit Care, 26 Feb 2025 ↗)

Authors' conclusion

In patients admitted to the ICU for de novo acute hypoxemic respiratory failure, dyspnea is associated with a higher risk of intubation and with a higher mortality.

Study context

Population
ICU patients with de novo acute hypoxemic respiratory failuredyspnea measured in 259
Participants
310 patients
Comparison
Dyspnea severity and association with intubation and 90-day mortality
Primary endpoint
Intubation (competing risks model accounting for ICU discharge)
Methodological detailscompeting risks model, Cox model
  • Competing risks model
  • Cox model

Primary result

As reported in the abstract

Baseline dyspnea and intubation

Subdistribution hazard ratio

1.96

P = 0.023

Moderate dyspnea

Subdistribution hazard ratio

2.61

P = 0.023

Severe dyspnea

Baseline median dyspnea-VAS
46 (IQR 16-65) mm
Dyspnea-VAS ≥ 40 mm at baseline
146 patients (56%)
Intubation rate
45%
SBP independently associated with intubation (sHR)
2.56, p < 0.001
Heart rate independently associated with intubation (sHR)
1.94, p = 0.02
PaO2/FiO2 independently associated with intubation (sHR)
0.34, p = 0.028

Further findings

90-day mortality
20%
Lower cumulative survival with baseline dyspnea-VAS ≥ 40 mm (logrank test)
P = 0.049
SAPS 2 ≥ 25 associated with mortality
P < 0.001
Moderate-to-severe dyspnea at baseline and mortality
P = 0.073
PaO2/FiO2 and mortality
P = 0.118
Treatment arm and mortality
P = 0.046

Original publication

Dyspnea is severe and associated with a higher intubation rate in de novo acute hypoxemic respiratory failure. Crit Care. Published 23 May 2024. doi:10.1186/s13054-024-04903-5

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.